2Curb JD,Abbott RD, Rodriguez BL,et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men [ J]. Circulation ,2003 ; 107 ( 15 ) :2016-20.
3Pence S, Yilmaz G, Yilmaz N, et al. Determination of plasma fibronectin and serum C-reactive protein in patients with cerebrovascular events [ J]. Int J Clin Pract,2003 ;57(2) :91-5.
4Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein [ J]. Curr Probl Cardiol,2004;29(8) :439-43.
5Sibelius U, Hattar K, Schenkel A,et al. Wegners granulomatosis anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response[ J]. J Exp Med, 1998;187 (4) :497-503.
6Myones BL, McCurdy D. The antiphospholipid syndrome : immunologic and clinical aspects, clinical spectrum and treatment [ J ]. J Rheumatol, 2000 ;27( Suppl 58 ) :20-3.
7Lawrence de Koning ABL, Werstuck GH, Zhou J, et al. Hyperhomocysteinemia and its role in the development of atherosclerosis[ J]. Clin Biochem,2003 ;36(6) :431-41.
5Yang X,Li Z,Zhao X,et al. Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China[J]. Stroke, 2016,47 (2) : 464- 470.
6Kim WJ,Park JM,Kang K,et al. Adherence to guidelines for antithromhotic therapy in patients with atrial fibrilla- tion according to CHADS2 score before and after stroke:a multicenter observational study from Korea [J]. J Clin Neurol,2016,12(1) :34-41.
7An SA, Kim J, Kim OJ, et al. Limited clinical value of multiple blood markers in the diagnosis of ischemic stroke [J]. Clin Biochem,2013,48(9) :710-715.
8Krishnamoorthy S, Khoo CW, Lim HS, et al. Prognostic role of plasma yon Willebrand factor and soluble E-selec- tin levels for future cardiovascular events in a real-world' community cohort of patients with atrial fibrillation[J]. Eur J Clin Invest,2013,43(10) :1032-1038.
9Kate M,Gioia L,Buck B,et al. Dabigatran Therapy in a cute ischemic stroke patients without atrial fibrillation [J]. Stroke, 2015,46 (9) : 2685-2687.
